Quince Therapeutics (QNCX) Profit After Tax (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Profit After Tax of $26.5 million for Q1 2026, up 276.03% year-over-year from $7.0 million in Q1 2025, and up 157.79% quarter-over-quarter from -$45.8 million in Q4 2025.
Quince Therapeutics (QNCX) Profit After Tax (2018 - 2026) Analysis & Trends
Quince Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at $26.5 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 276.03% year-over-year to $26.5 million; the TTM figure through Mar 2026 stood at -$44.6 million (up 28.26% YoY), while the FY2025 annual figure was -$84.0 million, down 40.18% from the prior year.
- Profit After Tax for Q1 2026 stood at $26.5 million, up from -$45.8 million in the prior quarter.
- The five-year high for Profit After Tax was $26.5 million in Q1 2026, with the low at -$45.8 million in Q4 2025.
- The 5-year median for Profit After Tax is -$11.8 million (2025), against an average of -$11.1 million.
- The sharpest annual moves came in 2024 and 2026: Profit After Tax slumped 520.0% in 2024, then jumped 276.03% in 2026.
- Quince Therapeutics' Profit After Tax stood at -$5.7 million in 2022, then surged by 164.42% to $3.7 million in 2023, then plunged by 520.0% to -$15.5 million in 2024, then tumbled by 194.63% to -$45.8 million in 2025, then jumped by 157.79% to $26.5 million in 2026.
- Business Quant data shows QNCX's Profit After Tax at $26.5 million in Q1 2026, -$45.8 million in Q4 2025, and -$13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | -75.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.46 Mn |
| Dec 31, 2025 | -45.79 Mn |
| Sep 30, 2025 | -13.44 Mn |
| Jun 30, 2025 | -11.85 Mn |
| Mar 31, 2025 | -15.03 Mn |
| Dec 31, 2024 | -15.54 Mn |
| Sep 30, 2024 | -3.16 Mn |
| Jun 30, 2024 | -28.47 Mn |
| Mar 31, 2024 | -11.15 Mn |
| Dec 31, 2023 | 3.70 Mn |
| Sep 30, 2023 | -5.09 Mn |
| Jun 30, 2023 | -4.67 Mn |
| Mar 31, 2023 | -11.93 Mn |
| Dec 31, 2022 | -5.74 Mn |
| Sep 30, 2022 | -7.92 Mn |
| Jun 30, 2022 | -16.56 Mn |
| Mar 31, 2022 | -22.07 Mn |
| Dec 31, 2021 | -23.16 Mn |
| Sep 30, 2021 | -21.71 Mn |
| Jun 30, 2021 | -21.83 Mn |